Design and development of novel agents for the treatment of animal trypanosomiasis

动物锥虫病（AT）是牛、骆驼、公牛和马等家畜的致命疾病，对新兴经济体和粮食安全造成巨大损害。现有的治疗方法既少又旧，而且耐药性很普遍。目前迫切需要新型抗感染药物来治疗AT。这个多学科项目将从我们的专利抗感染药物Strathclyde Minor Groove Binders（S-MGB）中开发出一种新的抗AT临床候选药物。这些抗感染药物是一个创新和令人兴奋的类别。与抗生素不同，它们的多模式作用机制与耐药性的恢复有关，包括世界卫生组织在内的全球组织对此进行了评论。该项目将涉及斯特拉斯克莱德大学斯科特小组内的药物设计，合成有机化学和化学生物学，使用最先进的设施和技术（核磁共振，质谱，目标接合分析）。在格拉斯哥大学的De Koning小组中，它将涉及测试新的抗寄生虫活性化合物。还将研究生物化学和细胞效应的性质。

Animal Trypanosomiasis (AT) is a fatal disease of livestock such as cattle, camels, oxen and horses, which does great damage to emerging economies and food security. Existing treatments are few and old, and resistance is widespread. Novel classes of anti-infective drugs to treat AT are desperately needed.This multi-disciplinary project will develop a new clinical candidate against AT, from our patented class of anti-infective agents, Strathclyde Minor Groove Binders (S-MGB). These anti-infective agents are an innovative and exciting class. Unlike antibiotics, their multi-modal mechanism of action is associated with resilience to drug resistance, which has been commented on by global organisations including the World Health Organisation. The project will involve drug design, synthetic organic chemistry and chemical biology within the Scott Group at the University of Strathclyde, using state-of-the-art facilities and techniques (NMR, Mass Spectrometry, Target engagement assays). In the De Koning Group at the University of Glasgow, it will involve the testing of new compounds for antiparasite activity. The nature of the biochemical and cellular effects will also be investigated.